Gabriela Pacheco-Sanchez, Rebecca Herrera, Margareta D Pisarska, Ricardo Azziz, Dequina A Nicholas, Jessica L Chan
{"title":"Multi-Racial Cytokine Profiling Reveals Immune Dysregulation not Chronic Inflammation in Polycystic Ovary Syndrome.","authors":"Gabriela Pacheco-Sanchez, Rebecca Herrera, Margareta D Pisarska, Ricardo Azziz, Dequina A Nicholas, Jessica L Chan","doi":"10.1210/clinem/dgaf524","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder often associated with chronic inflammation, but comprehensive characterization of immune markers across diverse patient populations is lacking.</p><p><strong>Objective: </strong>To determine whether PCOS exhibits a profile of chronic inflammation or immune dysregulation when analyzed across a diverse patient population.</p><p><strong>Design: </strong>Retrospective cross-sectional study of samples collected between 1987 and 2010 as part of the Androgen Excess Biorepository.</p><p><strong>Setting: </strong>Reproductive endocrinology clinics at the University of Alabama at Birmingham (UAB) in Birmingham, Alabama, and Cedars-Sinai Medical Center (CSMC) in Los Angeles, California, where women and adolescents presented for evaluation of androgen excess.</p><p><strong>Patients: </strong>40 premenopausal women (20 with PCOS, 20 controls) aged 18-45 years, categorized by race (Black and White) and PCOS diagnosis. Participants were race, age, and BMI-matched.</p><p><strong>Main outcome measures: </strong>Fasted follicular phase plasma concentrations of CRP and 96 circulating immune markers, including IL-6, TNF-α, and IL-18, measured using a Milliplex Luminex xMAP assay.</p><p><strong>Results: </strong>PCOS patients showed significantly lower levels of circulating immune markers (p<0.05). Growth factors (VEGF-A, PDGF), pro-inflammatory cytokines (IL-8, TNF-α, IFN-γ), and several chemokines were reduced in PCOS patients, independent of race. Only IL-18 and CXCL16 showed statistically significant differences between Black and White women.</p><p><strong>Conclusions: </strong>This study challenges the prevailing notion of PCOS as a disorder of chronic low-grade inflammation, suggesting instead that immune suppression and impaired angiogenic signaling may be factors in PCOS pathophysiology, especially in non-obese patients. Further research with larger sample sizes and inclusion of metabolic metrics is needed to confirm these findings before they can be applied in clinical practice.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of clinical endocrinology and metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/clinem/dgaf524","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Context: Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder often associated with chronic inflammation, but comprehensive characterization of immune markers across diverse patient populations is lacking.
Objective: To determine whether PCOS exhibits a profile of chronic inflammation or immune dysregulation when analyzed across a diverse patient population.
Design: Retrospective cross-sectional study of samples collected between 1987 and 2010 as part of the Androgen Excess Biorepository.
Setting: Reproductive endocrinology clinics at the University of Alabama at Birmingham (UAB) in Birmingham, Alabama, and Cedars-Sinai Medical Center (CSMC) in Los Angeles, California, where women and adolescents presented for evaluation of androgen excess.
Patients: 40 premenopausal women (20 with PCOS, 20 controls) aged 18-45 years, categorized by race (Black and White) and PCOS diagnosis. Participants were race, age, and BMI-matched.
Main outcome measures: Fasted follicular phase plasma concentrations of CRP and 96 circulating immune markers, including IL-6, TNF-α, and IL-18, measured using a Milliplex Luminex xMAP assay.
Results: PCOS patients showed significantly lower levels of circulating immune markers (p<0.05). Growth factors (VEGF-A, PDGF), pro-inflammatory cytokines (IL-8, TNF-α, IFN-γ), and several chemokines were reduced in PCOS patients, independent of race. Only IL-18 and CXCL16 showed statistically significant differences between Black and White women.
Conclusions: This study challenges the prevailing notion of PCOS as a disorder of chronic low-grade inflammation, suggesting instead that immune suppression and impaired angiogenic signaling may be factors in PCOS pathophysiology, especially in non-obese patients. Further research with larger sample sizes and inclusion of metabolic metrics is needed to confirm these findings before they can be applied in clinical practice.